Seller record · nextmeds.com

Nextmeds

Recorded September 2026 · Standard v1.1

Fails 2 of 8 criteria. S5, analytical documentation: Eight pages were read, covering home, about, contact, terms, privacy and the frequently asked questions, and none publishes a certificate of analysis, a lot number or a testing claim. 1 more criterion also fails; see the table below.

Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.

A telehealth membership selling compounded semaglutide and tirzepatide. It publishes a full plan ladder, and its headline figure is the twelve-month rung rather than the monthly one.

Operating entity Nextmeds, Inc.

Dispositions

Code	Criterion	Disposition	Where it was read
S1	Prescriber requirement	PASS	nextmeds.com
S2	Prescription gating	PASS	nextmeds.com
S3	Pharmacy identification	PASS	nextmeds.com
S4	Compounding disclosure	PASS	nextmeds.com
S5	Analytical documentation	FAIL	nextmeds.com
S6	Business address	FAIL	nextmeds.com/privacy
S7	Price disclosure	PASS	nextmeds.com
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

What was read, where, and on what date, for each disposition in the table above.

S1PASSMedical services, including clinical evaluation and prescribing, are stated to be provided by OpenLoop Healthcare Partners, PC and its affiliated professional medical practices.Source: nextmeds.com.

S2PASSThe order path was walked from the homepage and stopped at an eligibility intake headed check your eligibility for GLP-1 treatment, before any product or payment screen.Source: nextmeds.com.

S3PASSFour pharmacies named with street addresses and telephone numbers: RedRock Pharmacy in St. George, Health Warehouse in Florence, Precision Medicine in Bellmore, and Triad Rx in Daphne.Source: nextmeds.com.

S4PASSA reader-visible page states the medications are compounded and are not FDA approved or evaluated by the FDA.Source: nextmeds.com.

S5FAILEight pages were read, covering home, about, contact, terms, privacy and the frequently asked questions, and none publishes a certificate of analysis, a lot number or a testing claim.Source: nextmeds.com.

S6FAILFooter, contact, terms and privacy were read, and none prints a street address for the operating business. The only postal address printed on any of them belongs to Openloop, Inc. in Alpharetta, Georgia, which is the clinical platform rather than the seller.Source: nextmeds.com/privacy.

S7PASSA ladder printed on the homepage: compounded semaglutide at 79 dollars monthly, 76 on a 3-month plan, 73 on a 6-month plan and 49 on a 12-month plan; the headline figure is the 12-month rung.Source: nextmeds.com.

S8PASSNo letter names the entity in the FDA index, and no action has halted the business; control letter found in the same run.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide.

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.